Fact Source: Financial Supervisory Service DART / 2025-12-22
Disclosure Type: Execution of Single Sales/Supply Contract (Voluntary Disclosure)
💡 3-Second Summary
Samsung Biologics has announced an additional pharmaceutical Contract Manufacturing Organization (CMO) agreement worth approximately KRW 56.1B (USD 37.98M) with a European pharmaceutical company. This order accounts for 1.23% of its recent annual revenue, and the contract period runs for approximately 5 years until the end of 2030.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Contract Category & Title: Other Sales/Supply Contract / Contract Manufacturing Agreement for Pharmaceuticals (Voluntary Disclosure)
- Contract Amount: KRW 56,109,964,800 (Converted from the fixed contract value of USD 37,984,000 using the initial base exchange rate of KRW 1,477.20/USD as of December 19, 2025)
- Ratio to Revenue: 1.23% (Compared to the recent revenue of KRW 4,547,322,176,421 from the 2024 consolidated financial statements)
- Counterparty: A pharmaceutical company located in Europe (Identity and specific supply region are temporarily withheld due to operational confidentiality requirements; confidentiality expiration date is set to 2030-12-31)
- Contract Period: Start Date: 2025-12-19 ~ End Date: 2030-12-31 (Approximately 5 years)
- Contract (Order) Date: 2025-12-19
- Key Contract Terms: Down payment or advance payment is recorded as none (No). Specific payment terms are not provided in the disclosure text.
- Other Details: The contract expiration date and the information disclosure withholding period may change subject to mutual agreement. The disclosure does not state specific reasons for the change in earnings performance.
📈 2. [Expert View: What This Disclosure Means for Investors]
This regulatory filing serves as a voluntary disclosure confirming that Samsung Biologics has secured an additional mid-to-long-term order within its CMO business. The contract value of approximately KRW 56.1B accounts for a percentage (1.23%) of its recent annual revenue, and the details are disclosed under a voluntary framework to inform international markets.
Given that the contract explicitly defines a 5-year period, evaluations should be framed within this duration. The advance payment parameter is recorded as ‘None’, indicating no upfront payment is specified, and the absence of detailed payment terms presents an information restriction for public evaluation. Furthermore, the complete non-disclosure of the counterparty’s identity until the end of 2030 limits immediate portfolio verification. Since this contract is denominated in USD, minor adjustments in KRW-converted figures may occur depending on future foreign exchange rate movements. Investors should evaluate this disclosure based on the confirmed order figures rather than introducing speculative interpretations regarding disclosure triggers or accounting recognition schedules.
📝 Editor’s Comment (by K-STOCK Editor)
Samsung Biologics’ latest supply contract filing represents a voluntary disclosure of a transaction structured to guide investor expectations. Securing a 5-year contract worth KRW 56.1B from a European pharmaceutical company confirms an additional contract within the European region sharing the same order date (December 19). Although operational confidentiality clauses keep the client’s identity veiled until 2030 and no upfront payment is specified, the transaction establishes a verified backlog over the medium term, which carries a potential impact that may support manufacturing capacity utilization. Global investors should look past potential fluctuations from foreign exchange rates and focus on tracking the confirmed contract parameters over the long horizon.
📢 Disclaimer & Source Information
Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the individual investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
